A deal initially negotiated between Prothena Corporation plc and Celgene Corporation in 2018 continues to bear fruit, as Bristol Myers Squibb Company – which inherited the collaboration by buying Celgene – is opting in on a second candidate under the neuroscience partnership and option arrangement. On 28 May, BMS opted to acquire worldwide rights to PRX019, its second in-licensing decision under the deal, paying Prothena $80m in the process.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
